PDA
















ETC-216 UPDATES?

View Full Version : ETC-216 UPDATES?




Alex
  
This "super HDL" that can clear arteries of plaque was being
developed by Esperion Therapeutics.

Then, in the end of 2003, Pfizer takes over Esperion
Therapeutics, and I can't find anything at all about trials
of this new drug at the Pfizer website.

The old Esperion website, which now automatically links to
the Pfizer website, now says:

"By acquiring Esperion, we can bring our research
capabilities to bear on an emerging new area which has
potentially significant beneficial impact on patients.
Epidemiologic data and drug intervention trials both support
a strong correlation between higher HDL levels and
improvements in morbidity and mortality." Hank McKinnell,
Pfizer Chairman and CEO December 21, 2003

Is it just me, or does it look like Esperion's etc-216 is
in competition with Pfizer's new torcetrapib? http://www.- (http://www.-/)
pfizer.com/are/investors_reports/annual_2003/review/p2003-
ar14_15.htm

If anyone has more information on this drug, please
let me know.

Alex

Other articles for reference: http://www.clevelandclinic.or- (http://www.clevelandclinic.or-/)
g/heartcenter/pub/news/archive/2003/superhdl11_5.asp

Automatic Translations (Powered by Powered by Google):
BulgarianCroatianCzechDanishDutchEnglishFinnishFrenchGermanItalianJapaneseKoreanNorwegianPolishPortugueseSpanishSwedish
Translations delivered by vBET 3.2.2